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Abstract

Introduction: Scotland has introduced a number of initiatives to enhance prescribing of low cost generics versus originators and patent products in a class where these are seen as similar. Objective: Appraise the influence of the various measures on subsequent utilisation patterns and expenditure in high volumes classes to provide guidance. Methodology: Principally a narrative review of published studies. Results: Supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in (i) high INN prescribing, (ii) a considerable increase in prescribing efficiency for the PPIs, statins, renin-angiotensin inhibitor drugs and SSRIs. There were no specific activities encouraging prescribing of losartan vs. other ARBs or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilisation patterns post generics. Conclusions:  Multiple measures are needed to change physician prescribing habits. A authorities cannot rely on any ‘spill over’ effect even in closely related classes.  

Introduction

Scrutiny on pharmaceutical expenditure has intensified in recent years among health authorities and health insurance companies across Europe, with growth rates averaging 50% in real terms among OECD countries between 2000 and 2009 [1-5,101]. This growth will continue unless addressed, driven by well-known factors including changing demographics, rising patient expectations and the continued launch of new expensive drugs [3,4,6,7]. 

As a result, health authorities across Europe have introduced multiple reforms and initiatives to slow down, or even reverse it. The objective being to maintain the European ideals of equitable and comprehensive healthcare [3-7].

Key areas for reforms and initiatives have been measures to enhance the utilisation of low cost generic drugs versus originators or patented products in a class or related class, where the products are seen as similar in all or nearly all patients [1-5,9-11]. As a result, release considerable resources to fund new premium priced drugs and increased drug volumes without compromising patient care [3-5,9-12]. Initiatives in Scotland include measures to lower generic prices (Supply-side measures) as well as enhance their utilisation (demand-side measures). 

Supply-side measures and initiatives for generics in Scotland include the introduction of the ‘M’ (Manufacturer) and ‘W’ (Wholesaler) scheme in April 2005 to increase transparency in the manufacture and pricing of generics as well as any discounts and rebates offered by generic manufacturers to wholesalers and pharmacists to enhance the dispensing of their generics [5,10,12,102].  This led to an average 32.4% reduction in the prices of generics within the first year, resulting in an overall 2% reduction in pharmaceutical expenditure for that year [4,5,12,102]. Prices of high volume generics are now as low as 2% to 3% of pre-patent loss originator prices [3-5,10,12].

Concomitant with this, there have generally been no patient concerns with the prescribing of generics versus originators in Scotland. This is apart from a limited number of well-known cases including cyclosporine, lithium, phenytoin, theophylline modified release as well as long acting/ modified release diltiazem and nifedipine [12-14]. This is reflected by generally high voluntary INN (International non-proprietary name) prescribing rates in Scotland. These currently average over 80% across all products, rising to over 98% for high volume generics including generic lisinopril, omeprazole and simvastatin [4,5,10,15]. These high rates have been achieved through all physicians now trained in Scottish medical school to prescribe by INN, with follow-up in the community coupled with IT systems [3,5,10,11,15]. Follow-up in the community typically includes decision-support software as well as monitoring the prescribing of generics, which is seen as good-quality prescribing [5,10,15]. This compares with Austria where there is currently no INN prescribing with branded generics [16]. There is a similar situation in Germany with the manufacturers of branded generics offering discounts to the Sickness Funds to have their branded generic preferentially prescribed [4]. Similarly in Korea, with currently over 500 local generic manufacturers promoting their branded generics to physicians and pharmacists with limited demand-side measures [17]. Consequently, the current focus in Scotland regarding generics has been on seeking ways to enhance their prescribing versus patented products in a class or related class where pertinent and without compromising patient care.

The proton pump inhibitors (PPIs), statins and renin-angiotensin inhibitor drugs are seen as essentially similar in all or nearly all patients [3,4,11,15,18]. Consequently, providing an opportunity to increase the prescribing of multiple sourced versus patented products in each class or related class. As a result, conserving resources without compromising care. This has resulted in multiple policies among the Health Boards in Scotland to enhance the prescribing of generics versus patented PPIs, statins and ARBs [3,4,10,11,15]. There have also been initiatives to enhance the prescribing of generic SSRIs versus patented escitalopram [103-105]. The SSRIs have largely superseded traditional treatments such as tricyclic antidepressants (TCAs) in the management of depression in ambulatory care due to lower side-effects and safety in over dose [19-23]. They are all typically seen as having similar effectiveness and safety profiles, although potentially interpatient variation in their effectiveness and side-effects. This also applies to escitalopram [103-105], e.g. in 2002, the Scottish Medicines Consortium stated that ‘Escitalopram has been shown to be as effective as citalopram in short-term use and the health economic model submitted suggests that it is also cost-effective. However, the resource usage assumptions and clinical evidence underpinning the model are not robust and no clear benefits are demonstrated over citalopram or other effective and cheaper agents’ [103]. This lack of any perceived appreciable clinical difference between escitalopram and the other SSRIs, although considerable differences in acquisition costs, resulted in measures and initiatives among Health Boards in Scotland to limit its utilisation. These included prescribing indicators limiting the prescribing of escitalopram to less than 5% to 10% of all SSRI prescriptions [104,105], with follow-up by Health Board pharmacists and others. 

The availability of generic atypical antipsychotic drugs should also be welcomed in Scotland with generally low prices for generics versus the originator [8,10]. Clozapine was the first atypical antipsychotic drug to lose its patent, with published studies showing no difference in outcomes between the originator and generics once the problem with the first formulation in the US had been resolved [24-27]. More recently, generic risperidone became available in Scotland. However, it is recognised that schizophrenia and bipolar disorders are complex diseases to treat [28-30,106] and that atypical antipsychotic drugs should not be considered as a single class in view of the heterogeneity of their mechanism of action [29,30,106]. In addition, there can be substantial variation in the effectiveness of the different antipsychotic medicines between individual patients, and the number of side-effects seen can also differ substantially between patients. As a result, various authorities in Europe and the US recommend treatment should be individualised [30,31,106]. Consequently, potentially limiting the number of demand-side measures that could possibly be introduced in Scotland to preferentially enhance the prescribing of generic oral atypical antipsychotic drugs first line where pertinent. This is apart from possibly educational initiatives suggesting to psychiatrists that they should start patients on a generic oral atypical antipsychotic drug where possible. This mirrors the advice given by the National Institute of Health and Clinical Excellence (NICE) [106]. 

The Health Boards in Scotland also faced challenges following the introduction of generic clopidogrel in August 2009. The challenges resulted from manufacturers able to address the technicalities of PLAVIX’s European patent through producing clopidogrel in a different salt [8]. However, generic clopidogrel was only initially launched for secondary prevention of atherosclerotic events, i.e. without the Acute Coronary Syndrome (ACS) indication [8]. The European Medicines Agency (EMA) subsequently approved various generic clopidogrel preparations through its centralised procedure in 2009. However, concerns were raised by the manufacturer and others whether changing the salt would subsequently alter the toxicity, stability and rate of absorption of the active drug [8]. Concerns over the quality of generic clopidogrel were also raised by the originator company when the EMA in March 2010 recalled one of the generic clopidogrel preparations due to concerns with its manufacture [8]. However, the prescribing of generic clopidogrel could potentially release considerable resources in Scotland and other European countries given its existing high sales.

The objective of this review article is to appraise the influence of the variety of measures and initiatives introduced in Scotland during the past decade among a number of high volume classes on their subsequent utilisation patterns and expenditure. Subsequently, use the findings to give guidance on possible measures and initiatives that health authorities or health insurance companies in other countries could potentially introduce to further enhance their prescribing efficiency.

Methodology

We conducted a narrative review of the extensive number of publications written by the co-authors regarding generics. These were subsequently combined with  additional references and unpublished data known to the co-authors where pertinent. We did not undertake an extensive review of the literature regarding generics, as such reviews have already been undertaken [4,5,9,16, 32-34]. We have employed a similar methodology in other publications regarding generics [3-5,10-12,15,18]. No attempt has been made to assess the quality of the referenced papers using for instance a modified Jadad scale [35] as most of the cited publications involved the co-authors. In addition, we included web-based references from national and regional health authorities, including England and Scotland, where pertinent to provide additional background data.

Data from the National Health Services Scotland Warehouse was used to analyse the trends in utilisation and expenditure for the SSRIs [10]. Defined daily doses were used to capture the utilisation data. This is in line with International recommendations [36,37,107]. 

Results

PPIs and statins

Table 1 contains details of the multiple demand side measures instigated for both the PPIs and statins in Scotland between 2001 and 2007 to improve the quality and efficiency of prescribing for acid-related stomach disorders and hypercholesterolaemia [3,5,10]. Generic omeprazole became available in 2002 and generic simvastatin in 2003 [3]. These have been collated under the 4Es – education, engineering, economics and enforcement [38]. Education refers to initiatives such as guidelines, benchmarking and academic detailing; engineering refers to organisational or managerial interventions such as prescribing indicators; and economics refers to financial incentives such as physician financial incentives for achieving agreed prescribing targets [38]. Enforcement refers to regulations such as prescribing restrictions, which have been introduced for the statins in a number of European countries including Austria, Croatia and Sweden and compulsory generic substitution [3,4,9,11,39]. There are currently no prescribing restrictions in Scotland; consequently this is not contained within Table 1.

Table 1 – Demand side measures introduced in Scotland between 2001 and 2007 for the PPIs and statins [3,10]. These continued after 2007

Measure	Examples of initiatives categorised under the 4Es
Education	Physicians typically trained in medical school to prescribe by INN name with follow up in the community coupled with IT systems. Follow up includes decision support software as well as monitoring the prescribing of generics, which is seen as good-quality prescribing. This has resulted in current INN prescribing rates averaging over 80% across all products, rising to over 98% for generic simvastatin and generic lisinoprilNational guidance and guidelines (SIGN) for dyspepsiaNational guidance and guidelines (SIGN) for primary and secondary prevention including patients with diabetesRegional formularies for PPIs and statins such as the Lothian and Greater Glasgow formularies advocating generic omeprazole and generic simvastatin; the latter as 40mg generic simvastatin General monitoring of prescribing, benchmarking and academic detailing
Engineering	Better Care Better Value’ indicators to enhance the prescribing of low cost statins and PPIs versus single sourced statins and PPIsQuality targets for statin prescribing as part of Audit Scotland in 2003Quality and Outcome Framework targets including those for diabetes, hypertension, stroke and CHD. This included patient targets for lipid levels and blood pressureTherapeutic switching by Health Board pharmacists when working with GPs
Economics	Practice based financial incentive schemesPayment by result schemes (Quality and Outcome Framework)
*NB – SIGN stands for Scottish Intercollegiate Guidelines Network. SIGN develops guidelines involving all key stakeholder groups, with the emphasis on local ownership and implementation. As a consequence, providers of care in Scotland are expected to follow the guidance, and provide justifications if the standard of care differs appreciably from this [10].

This is similar to the multiple demand-side measures introduced in Sweden to enhance prescribing efficiency (Table 2). Both greater than the more limited demand-side measures introduced for the PPIs and statins in France, Ireland and Portugal between 2001 and 2007 (Table 2) [3,11], although this is changing in France with the introduction of pay-for-performance programmes since 2009 (Table 2). 

Table 2 – Demand-side measures introduced in France, Ireland, Portugal Sweden between 2001 and 2007 [Adapted from references 3-5,11]

France	EducationGuidelines from national authorities including those for the management of hypercholesterolaemia Health insurance companies benchmarking GPs with their colleagues and providing continuous feedback on generic prescribing rates; however limited incentives or sanctions outside of the CAPI scheme (below)Government promotional campaigns  to enhance the acceptance of generics and INN prescribing among patients Health insurance companies promoting generics on the back of reimbursement forms sent to patientsEngineeringTargets established for generic substitution rates among community pharmacistsPrice: volume agreements for existing drugs with pay back mechanisms for over budget expenditureThe CAPI (Contrats d’amélioration des pratiques individuelles) system was introduced in 2009 to improve prevention, consolidate the quality of care for patients with chronic diseases and optimise efficient prescribing. Quality targets include those for vaccinations and chronic diseases. Efficiency targets to increase prescribing of generics included those for generic antibiotics versus all antibiotics (target = 90%), generic PPIs versus all PPIs (target = 85%), generic statins versus all statins (target = 70%), generic antidepressants versus all antidepressants (target = 80%) and generic drugs for hypertension versus all antihypertensive drugs (target = 65%). The CAPI project Initially applied to a minority of patients but since 2012 has been extended to all GPs in FranceEconomicsAmbulatory care physicians agreed to prescribe by INN name in return for higher fees (initial target - 25% of all prescriptions).Under the CAPI system, GPs received an additional payment for improving the care of patients against agreed standards. Initially, the maximum payment was €6000/ GP (no penalties for failing). More recently there is a potential bonus of €9100/general practitioner, with a maximum of €2800 for efficient prescribing of generics versus patented drugsPatients pay a higher co-payment for a more expensive product that the current reference priced molecule.  Alongside this in 2006, there was an agreement with pharmacists whereby patients who refuse generic substitution will have to pay the full health insurance component of their prescription and subsequently claim this back. If they accept, this component is paid by the pharmacistPatients pay up to 35% co-payment for PPIs and statins (0% if part of agreed long term illness); overall approximately 20% co-payment. This is typically covered by additional insurance taken out by patientsEnforcementPharmacists can substitute if the generic drug is less expensive than the originator
Republic of Ireland	EducationPublished guidelines – however not enforcedOverall, currently no incentives or sanctions encouraging GPs to prescribe generic drugs rather than originators or single sourced products in a class.
Portugal	EducationTreatment guidelines (although not mandatory) alongside pharmacy educational programmesInformation campaigns to patients and healthcare professionals promoting the quality of generics and their impact with controlling pharmaceutical expenditure. Patient campaigns via TV, radio, leaflets in hospitals, healthcare centres and pharmacies as well as bill boards and the internetPhysicians updated every quarter by INFARMED (Portuguese Medicines Agency) of available generics (Pharmaceuticals Generics Guide and Reference Price Guide); also available electronicallyCurrently though no incentives or sanctions for physicians to prescribe generic drugs with minimal monitoring of physician prescribing behaviourEconomicsReference Price System (RPS) introduced in 2002 defining a fixed amount paid by the National Health Service (NHS) for the molecule (homogeneous group) with patients required to fund the difference for a more expensive product  EngineeringPrice: volume agreements between the Portuguese Pharmaceutical Industry (APIFARMA) and the Ministry of HealthEnforcement Since 2002, obligation by physicians to prescribe by INN name for medicines with approved generics; however physicians can prohibit substitution where concernsSince 2002, pharmacists are allowed to substitute generics (where physicians prescribe INN name and do not prohibit substitution), and should inform patients about the prices of generics. There is though currently no financial incentives by law to encourage pharmacists to preferentially dispense generics 
Sweden	EducationGuidance and guidelines for the statins including the Wise List in Stockholm County Council (similarly guidance regarding the prescribing of PPIs)Benchmarking of prescribing habits coupled with continuous feedback Computerised decision support tools to enhance the quality and efficiency of prescribingMandatory to have at least one DTC in each County (Region) enhancing the rational use of drugsEngineering Prescribing targets among the individual counties (regions) to enhance the prescribing of generics first line where standard such as generic omeprazole versus all PPIs and generic simvastatin versus all statinsEconomics Financial incentives to GPs for achieving agreed prescribing targetsIncreasingly devolved drug budgets to primary healthcare centres (groups of GPs) with the opportunities for savings for achieving targetsPatient co-payment for more expensive branded generics or originators than the current referenced priced moleculeEnforcement National prescribing restrictions on new and existing drugs where concerns with their value in all or some populations. This recently included rosuvastatin and atorvastatin (June 2009)Compulsory generic substitution with the cheapest available product for the molecule -  enhanced by the introduction of technical support systems enabling pharmacists to continually stock the cheapest product (recently replaced by monthly auctions for generics to supply the Swedish market the following month)Physicians can indicate ‘no substitution’ although this is rare in practice. In addition, the Medicines Product Agency indicates to physicians and pharmacists which products are not substitutable 

PPIs

The multiple demand-side measures introduced in Scotland between 2001 and 2007 (Table 1) resulted in omeprazole continuing to drive the increase in PPI utilisation, with stable utilisation of the other PPIs including esomeprazole. Omeprazole was almost exclusively generic omeprazole on a DDD basis (defined daily dose) once available, with rates of over 98% of total omeprazole utilisation since 2006 [10]. 

Expenditure/ DDD for generic omeprazole continued to fall following the various demand-side initiatives (Table 1) as well as following the introduction of the ‘M’ and ‘W’ scheme [10]. These supply- and demand-side measures continued after 2007 resulting in expenditure/ defined daily dose (DDD) of generic omeprazole in 2010 91% below 2001 originator prices. As a result, expenditure/ 1000 inhabitants/year in 2010 in Scotland was GB£5481 (€6301), 56% below 2001 levels despite a 3 fold increase in utilisation during this period [10]. 

We calculated expenditure/ 1000 inhabitants/ year for the PPIs in 2010 would have been £35934 (€41324) assuming no reductions in expenditure/ DDD for the PPIs since 2001 and similar utilisation patterns [10]. This led to potential savings of over GB£159mn alone in 2010 in Scotland for the 5.2million population [10].

Statins

Simvastatin continued to dominate statin utilisation from 2001 onwards, reaching 57% to 58% of total statins (DDD basis) between 2007 to 2010  following the multiple demand-side measures (Table 1), with stable utilisation of both atorvastatin and rosuvastatin [10]. This was increasingly higher strength statins for both simvastatin (Figure 1) and atorvastatin helped by the inclusion of lipid level targets in the Quality and Outcomes Framework (QoF) (Table 1), published studies and SIGN guidance advocating 40 mg simvastatin [10] (Table 1).



Figure 1 – Number of different strength simvastatin tablets dispensed in Scotland 2000 to 2010 [Ref 10 – reproduced with kind permission of the journal]


Higher strength simvastatin (40 and 80mg) accounted for 85% of total simvastatin DDDs in 2010; slightly greater for higher strength atorvastatin (20, 40 and 80mgs) at 94% of total atorvastatin DDDs. This was nearly all 40mg for simvastatin, averaging 94% to 97% of higher strength statins between 2005 and 2010 [10].

Simvastatin was typically generic simvastatin, averaging 98% of all simvastatin utilisation on a DDD basis since 2006 [10]. This coupled with continued low prices for generic simvastatin, at 97% below 2002 originator prices in 2010, led to reimbursed expenditure up only 7% in 2010 compared with 2001, at GB£11420/ 1000 inhabitants (€13113) [10]. This was despite a 6.2 fold increase in statin utilisation during this period. We believe expenditure/ 1000 inhabitants/ year for the statins in 2010 would have been £67256 (€77345) assuming no reduction in expenditure/ DDD for the statins since 2001 and similar utilisation patterns. This lead to potential savings of over GB£290mn in 2010 [10].

Comparison with other European countries

There were more limited demand side measures in France, Ireland and Portugal encouraging the preferential prescribing of generic PPIs and statins between 2001 and 2007 (Table 2)l [3-5,11]. This resulted in a decrease in the utilisation of omeprazole, and an increase in the utilisation of esomeprazole, in each of these three countries following the availability of generic omeprazole [3]. Similarly in these three countries during this time, an increase in the utilisation of patented atorvastatin and rosuvastatin following the availability of generic simvastatin [3]. As a result, considerable differences in overall prescribing efficiency between Scotland and these three countries between 2001 and 2007 following the availability of generic omeprazole and simvastatin, with all PPIs and statins seen as essentially similar in all or nearly all patients (Table 2) [3-5,9-11]. 



Table 3 – Influence of supply and demand measures on prescribing efficiency between 2001 and 2007 for both PPIs and statins among selected Western European countries [Adapted from reference 3]

Country	Class	Utilisation 2007 vs. 2001	Expenditure 2007 vs. 2001
France	PPI	↑ 2.1 fold	↑ 38%
	Statin	↑ 72%	↑ 19%
GB – Scotland	PPI	↑ 2.4 fold	↓ 52%
	Statin	↑ 4.9 fold	↑ 16%
Ireland	PPI	↑2.4 fold	↑ 2.6 fold
	Statin	↑7.1 fold	↑4.9 fold
Portugal	PPI	↑ 3.1 fold	↑1.9 fold
	Statins	↑ 4.3 fold	↑2.3 fold

Multiple demand-side measures also appreciably enhanced prescribing efficiency in Sweden for both the PPIs and statins between 2001 and 2007, e.g. PPI and statin utilisation increased by 42% and 2.5 fold respectively but expenditure decreased by 48% and 51% respectively [3]. Expenditure/ 1000 inhabitants/ year for both classes in 2007 was under Euro6000, one tenth of that seen in Ireland, although for a less co-morbid population [3].

Renin-angiotensin inhibitor drugs

ACEIs versus ARBs

Various demand-side measures were implemented in Scotland between 2001 and 2007 to enhance the prescribing of generic ACEIs versus patented ARBs (Table 4), with the drugs in both classes seen as essentially similar in most patients [15]. This was because prospective clinical studies showed a dry cough only occurred in approximately 10% of patients prescribed ACEIs, with only 2% to 3% of patients in ACEI clinical trials actually discontinuing these drugs due to a dry cough [4,15,40-42,108]. These findings led the Office of Fair Trading to suggest that ARBs should only comprise a maximum of 5% of total prescriptions of all renin-angiotensin inhibitor drugs [108]. Having said this, published studies have shown a dry cough can occur in up to 25% of patients in selected populations especially those prescribed higher doses [15,43].



Table 4 - Demand side measures in Portugal and Scotland (national and among the Health Boards) to enhance the prescribing of ACEIs first line included between 2001 and 2007 [Adapted from Reference 15]

Country	Demand-side measures
Portugal	Demand side measures - General and for ARBs:Education - includes guidelines (although not mandatory) and campaigns promoting generics. However, limited activities compared with a number of other Western European countries Economics - includes establishing a fixed price for the molecule (in homogeneous groups) with patients paying the difference if they wish a more expensive brand. Currently though no financial incentive programmes for physicians to enhance the prescribing of generics Enforcement - includes since 2002 an obligation for physicians to prescribe by INN name. However not enforced and physicians can prohibit substitution where there are patient concerns. Pharmacists can substitute generics where physicians have prescribed by INN – not otherwise - and should also inform patients about generic prices versus originators (however no financial incentives for this limiting activities in practice)
Scotland	Education - national and local prescribing guidance from individual Health Boards as well as from the SIGN, benchmarking among physicians in the same Health Board, academic detailingEconomics - Physician financial incentives for achieving prescribing goals including prescribing targets. This includes prescribing targets for ACEIs vs. ARBs as well as blood pressure targets in patents with hypertension, diabetes or coronary heart disease as part of the Quality and Outcome Framework targets (QoF) introduced in 2004Engineering – included prescribing targets for ARBs as a % of all renin-angiotensin inhibitor drug prescriptions by volume (initiated as part of Audit Scotland in 2003). These include >25% by prescribing volume (Lothian Health Board)

These activities led to low utilisation of ARBs in Scotland versus Portugal between 2001 and 2007  (Figure 2). There were similar ARB utilisation patterns in Scotland to both Austria and Croatia (Figure 2) [15]. The authorities in both these countries had instigated prescribing restrictions limiting the prescribing of ARBs to patients experiencing tolerance or side-effect problems with ACEIs [4,5,9,15]. These restrictions were backed up with financial penalties for physicians suspected of abuse to help enhance adherence, although their intensity varied between the two countries. There was greater follow up of prescribing restrictions in Croatia, leading to differences in practice in subsequent ARB utilisation profiles between these two countries (Figure 2) [5,9,15].



Figure 2 – % utilisation of ACEIs vs. all renin-angiotensin inhibitor drugs (DDD basis) 2001 to 2007 among selected European countries [Adapted from Ref 8]




As a result, there has been stable expenditure on renin-angiotensin inhibitor drugs in Scotland between 2001 and 2007 versus growing expenditure in Portugal (Figure 3) [15]. This was despite a 159% increase in utilisation (DDD basis) in Scotland between 2001 and 2007, helped by low prices for generic ACEIs and limited utilisation of ARBs. Utilisation of renin-angiotensin inhibitor drugs increased by 69%, 89% and 72% in Austria, Croatia and Portugal respectively between 2001 and 2007 [15]. Generic enalapril and lisinopril were 88% below pre-patent loss prices in Scotland in 2007, and accounted for 98% to 99% of total enalapril and lisinopril on a DDD basis in 2007 [15].

Figure 3 – Expenditure/ 1000 inhabitants/ year for renin-angiotensin inhibitor drugs among selected European populations [Adapted from Ref 15]






Losartan vs. patented ARBs

Losartan’s patent expired in the UK in March 2010, with the first generics reimbursed in Scotland in July 2010 when losartan was listed on the Drug Tariff. Consequently, Health Boards should be active in Scotland encouraging GPs to start patients on losartan when an ARB is indicated, as well as switching patients on other ARBs to losartan [44]. This particularly as £26.27million was spent on ARBs in Scotland in 2009, making ARBs the seventh most expensive drug class in Scotland, and the price of losartan was falling rapidly following its availability [45]. In addition, all ARBs are seen as equally effective for the management of hypertension and heart failure at appropriate doses [44,46-48], although care may be needed with switching patients with heart failure to losartan to save costs [45,109].

However, there were no specific activities among the Health Boards to increase the prescribing of generic losartan versus existing patented ARBs [45]. This was because therapeutic switching programmes and other active measures would entail considerable Health Board resources both in time and costs when generic valsartan, candesartan and irbesartan would shortly become available on the Drug Tariff [45]. In addition, other higher priority areas had already been identified to improve the quality and efficiency of primary care prescribing in Scotland in 2012 and some of these would be compromised by concentrating on generic losartan [45]. Multiple demand-side measures had already successfully limited ARB utilisation in Scotland (Figure 2), and there would be savings anyway from the availability of generic losartan versus the originator due to the low envisaged price for generic losartan [45]. 

There was no appreciable change in the utilisation of losartan following the availability of generics, rising by 4% on a moving annual total basis (DDDs) one year after the availability of generic losartan [45]. There was a similar pattern when assessing the utilisation of losartan as a % of all single ARBs following the availability of generic losartan (Table 5). This compared with a significant increase in losartan utilisation following the availability of generics in Austria and Belgium (Table 5). In both countries, prescribing restrictions were removed for losartan but not for the other ARBs [49,50]. The other ARBs could only be prescribed in patients intolerant to ACEIs or experiencing unacceptable side-effects [49,50]. In Sweden, multiple demand-side measures were introduced similar to those for PPIs and statins (Table 12) along with  therapeutic switching [51]. This also resulted in a significant increase in the utilisation of generics post generic losartan (Table 5). There was also an appreciable increase in the utilisation of losartan versus other ARBs post generic losartan in Bury PCT following therapeutic switching programmes combined with other measures including guidelines, prescribing targets and financial incentive programmes in March 2011 [5,52].

Table 5 – % utilisation of losartan versus other single ARBs (DDD basis) before and after the availability of generic losartan (month zero) among selected European countries [45,49-51.53]


NB. DDDs = defined daily doses

Losartan was typically generic losartan in Scotland after its launch, averaging between 98% and 99% of all losartan on a DDD basis from August 2010 [45]. 

In March 2012, the reimbursed price (drug tariff price) of losartan 50mg in Scotland was GB£0.056p/ day, 88% below pre-patent loss prices [45]. This led to estimated savings of nearly £8million/ year in Scotland just from the availability of generic losartan alone versus the pre-patent loss situation [45].

SSRIs

The demand side measures among the Health Boards in Scotland described earlier, following advice from SMC [103], led to low utilisation of escitalopram in Scotland (Table 6). This compares with Ireland and Portugal (Table 6) with their limited demand side measures generally to combat pharmaceutical company marketing activities (Tables 2 and 4).

Table 6 – % Utilisation of escitalopram versus other SSRIs (DDD basis) 2001 to 2007 among selected European countries


NB. Population in Ireland is the GMS population with greater co-morbidity than the general population [3,11]

There was also high INN prescribing for the SSRIs on a DDD basis in Scotland in 2007 suggesting limited concerns with generic SSRIs in practice, e.g. fluoxetine, paroxetine and sertraline were 98% generics in 2007 and citalopram 99%. This coupled with low prices for generic SSRIs, e.g. generic citalopram in 2007 was 84% below pre-patent loss prices, generic fluoxetine in 2007 was 88% below and generic sertraline 89% below pre-patent loss prices in 2007, substantially lowered SSRI expenditure in recent years in Scotland (Table 6). This compares with appreciably increased expenditure in both Ireland and Portugal in 2008 and 2007 versus 2001 respectively (Table 7). 

Table 7 – Expenditure/ 1000 inhabitants/ year for SSRIs among selected European countries (Euros)


NB. Population in Ireland is the GMS population with greater co-morbidity than the general population [3,11]

Overall between 1998 and 2007, the utilisation of SSRIs increased 2.37 fold in Scotland but overall expenditure decreased by 59%. This resulted in considerable resource savings without appearing to compromise care. However, specific research is needed among patients before we can make any definitive statements.

Generic atypical antipsychotic drugs

There was limited Health Board activity in Scotland following the availability of generic oral risperidone in view of the recognised need to tailor therapies for patients with schizophrenia or bipolar disorders [54]. This was apart from suggesting to psychiatrists that they start patients on a generic oral atypical antipsychotic drug where possible [54]. 

There was a 53% increase in the utilisation of selected atypical antipsychotic drugs in Scotland in recent years, rising from 3.4DDDs per one thousand inhabitants per year in 2005 to 5.1 in 2010 [54]. This was driven by increasing utilisation of olanzapine, quetiapine and aripiprazole, although there have been concerns with some of the activities of commercial companies [54]. There was limited influence of the availability of generic oral risperidone in April 2008 on its subsequent utilisation. Overall, the utilisation of risperidone decreased steadily from 21% of total atypical antipsychotic drugs (DDD basis) in 2005 to 16% in 2010 [54]. This mirrored the situation in other European countries during this period with again increasing recognition of the need to tailor treatment with atypical antipsychotic drugs [30,55,56].

There was again high utilisation of oral generic risperidone in Scotland, with INN prescribing averaging 93% to 98% of total oral risperidone on a DDD basis following the availability of generics. This suggests no problems with generic oral risperidone in practice [54]. However, research among patients is needed before we can make any definitive statements.

Reimbursed expenditure for the selected atypical antipsychotic drugs grew by 42% during this period, increasing from £4662/ 1000 inhabitants/ year in 2005 to £6512/ 1000 inhabitants/ year in 2010 [54]. This was lower than the increase seen with their utilisation, facilitated by reimbursed expenditure/ DDD for generic oral risperidone at GB£0.47p in 2010, 84% below pre-patent loss prices. This reduction in expenditure/ DDD for generic oral risperidone reduced expenditure for risperidone in 2010 in Scotland by GB£3.19million compared with the pre-patent loss situation [54].  Expenditure on atypical antipsychotic drugs should start falling in Scotland with oral olanzapine losing its patent at the end of 2011 and quetiapine in March 2012, with these two the most prescribed atypical antipsychotic drugs in Scotland [54].

Clopidogrel

In Scotland, there was a pragmatic approach to the availability of generic clopidogrel with Health Board Drugs and Therapeutics Committees recommending its prescribing rather than PLAVIX in view of the potential resource savings and no perceived problems [8]. A similar situation was seen among a number of other European countries and regions despite the efforts of the originator company, endorsing the approach taken in Scotland [8]. The authorities in France recently fined the originator company for the disinformation regarding generic clopidogrel [110]. Hopefully, this will help reduce such disinformation in the future

Again, the prescribing of generic clopidogrel was enhanced by high INN prescribing rates in Scotland (Education) generally coupled with benchmarking and academic detailing (Education) as well as financial incentives for general practitioners (Economics) [8].The only current recommendations regarding generic clopidogrel are concerning specific salts to dispense in nursing homes when the packs are broken down for unit dispensing, as there can be stability concerns [8]. 

This contrasts with Korea where the originator PLAVIX still accounted for over 80% of clopidogrel utilization in 2009 despite 37 branded generics launched between 2006 and 2009 [17]. Limited supply-side measures meant the cost of PLAVIX only decreased by 13% in 2009 compared to pre-patent loss prices where-as there was a 40% price reduction for generics. Utilization of clopidogrel rose by 173% between 2006 and 2009, with most of this increase attributable to the originator (126% increase). The lack of measures and initiatives in Korea such as a reference pricing system for the molecule, limited transparency in the pricing of generics as well as no demand-side measures such as INN prescribing or generic substitution appreciably, reduced resource savings in Korea versus Scotland. Generic clopidogrel in Scotland was already 93% below pre-patent loss prices by July 2011 [8].

INN Prescribing

The teaching of INN prescribing in Scottish medical schools, with follow-up in the community, translated into high utilisation of generics vs. originators in all classes and products studied, e.g. PPIs, statins, renin-angiotensin inhibitor drugs, SSRIs and oral risperidone (Table 8).



Table 8 – Consolidated % utilisation of multiple sourced products (generics) vs. total utilisation in Scotland for the molecule (DDD basis) across multiple products and classes [10,15,45,54]


NB. PPI = proton pump inhibitor, ACEI = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin Receptor Blocker; SSRI = Selective Serotonin Re-uptake Inhibitor; DDDs = defined daily dose

Discussion

From a policy perspective, we believe these findings confirm those of other authors  that multiple demand-side measures are needed to favourably influence physician prescribing habits [57,58]. This was seen with the resultant changes in the utilisation patterns of PPIs, statins and ACEIs vs. ARBs in Scotland versus France, Ireland and Portugal. As a result, leading to considerable differences in overall prescribing efficiency (Table 3, Figure 3) among these four countries, with the products seen as essentially similar in all or nearly all patients. Without these measures, spending on the PPIs, statins and renin-angiotensin inhibitor drugs would have been considerably higher in Scotland without improving care [10,15].

The multiple demand-side measures also limited the prescribing of escitalopram in Scotland (Table 6). This compares to the situation in Ireland and Portugal were there was increasing utilisation of patented escitalopram despite the availability of generic SSRIs with their limited demand-side measures (Table 7). As a result, decreasing expenditure on the SSRIs in Scotland between 2001 and 2007 despite appreciably increased volumes versus appreciably increased expenditure in both Ireland and Portugal (Table 7). 

Interestingly, the multiple demand-side measures for the renin-angiotensin inhibitor drugs in Scotland appeared to have a similar influence on limiting ARB prescribing compared with the instigation of prescribing restrictions, coupled with financial incentives, in both Austria and Croatia (Figure 2). As a result, provide guidance to other health authorities on potential measures to further enhance the quality and efficiency of their prescribing where there is no possibility of introducing prescribing restrictions.

The need for multiple measures to favourably influence prescribing habits is also endorsed by the lack of change in the utilisation patterns of either losartan [45] or risperidone in Scotland and other European countries [54-56] following the availability of generics. This suggests no ‘spill over’ effect in practice between classes even when these are closely related as seen with the renin-angiotensin inhibitor drugs. Consequently, health authorities cannot rely on the transfer of learnings from one class to another to effect changes in physician prescribing habits. This is potentially exacerbated on this occasion by a greater complexity with the message for generic losartan, e.g. changing from emphasising ACEIs vs. ARBs to ACEIs plus low cost ARBs vs. patented ARBs [45]. In addition, greater complexity with treating patients with schizophrenia and bipolar disorders than for instance acid-related stomach disorders, or hypertension, with the need to tailor treatments to optimise outcomes [54]. 

We believe the QoF targets, combined with recent SIGN guidance, helped reinforce and enhance the utilisation of higher strength statin tablets, providing guidance to other health authorities [10]. This is because, in comparison, the average dispensed dose of simvastatin in Stockholm, Sweden, in 2008 was only 20.4mg, with 35% dispensed 10mg and only 25% higher strength simvastatin [2,10]. The prescribed dose of simvastatin for secondary prevention patients in Ireland also averaged a similar rate at only 22mg [10,59], with physicians in both countries having access to the same published medical literature. However, it is difficult to substantiate this would further specific research. We also believe the greater increase in utilisation of the renin-angiotensin inhibitor drugs in Scotland between 2001 and 2007 compared with Austria, Croatia and Portugal may again be linked with the instigation of QoF blood pressure targets in patients with hypertension, diabetes and CHD coupled with considerable financial incentives for physicians achieving the highest target levels [15]. However, again it is difficult to substantiate without access to individual patient records.  

The high utilisation of generics in Scotland (Table 8) versus the originators suggests again limited concerns generally with generics among both patients and physicians. We believe this provides guidance to other countries where there are concerns with the prescribing of generics. However as mentioned, this requires more substantial research before we can make definitive statements. We also believe the high utilisation rates for generics versus originators are enhanced by the teaching of INN prescribing in medical school, with follow-up in the community.

Finally, we believe high INN prescribing helps address potential patient confusion and possible concerns if they are dispensed different branded generics on each occasion [2,10,60,]. This can lead to potential duplication of prescriptions and/ or poor compliance if not fully addressed [2,3,59].  High INN prescribing also reduces the need to incentivise pharmacists to achieve agreed substation targets, e.g. France, or the need to spend valuable time and resources educating patients about the quality of generics to overcome concerns, e.g. France and Portugal [4,5]. Such an approach would also certainly help countries such as Korea.

The pragmatic approach taken in Scotland with the availability of generic clopidogrel [8], and no perceived problems in practice, suggests that manufacturers can launch new generics in different salts and without all the indications provided bioequivalence has been satisfactorily demonstrated to the originator [8].

In conclusion, we believe that despite the limitations in our research including no formal systematic review for the reasons stated, the findings from the various disease areas and classes in Scotland provide guidance to health authorities and health insurance companies on potential ways forward to further enhance the quality and efficiency of their prescribing. This has been achieved by reviewing a number of cases histories and comparing the findings with those from a number of  different European countries. We are already seeing countries learning from each other. These include increased transparency in the pricing of generics to lower their prices, e.g. Lithuania [61], measures to enhance INN prescribing, e.g. Abu Dhabi, France and Lithuania [1,61,62], pragmatic approaches to enhancing the use of generics even when different salts and indications, e.g. clopidogrel [8], prescribing targets linked to financial incentives, e.g. France and Spain [1,19], as well as strict follow-up measures to enforce prescribing restrictions, e.g. Croatia and the Republic of Srpska [15,63]. This will grow especially in Europe to maintain the ideals of equitable and comprehensive healthcare in the face of continued resource pressures. 

Key issues

	Authorities continue to scrutinise pharmaceutical expenditure in view of its rapid growth compared with other components of health care and ongoing pressures. Pressures include ageing populations and the continued launch of new premium priced products

	Reforms and initiatives to help moderate the growth in pharmaceutical expenditure during the past decade in Scotland include measures to encourage the prescribing of low cost drugs versus originators as well as versus patent products in a class where the products are seen as similar in all or nearly all patients. The former includes educational and other initiatives to encourage high INN prescribing rates, with the latter including guidelines, formularies, academic detailing, prescribing targets and financial incentive schemes

	Multiple measures appreciably enhanced prescribing efficiency in Scotland versus other European countries with limited demand side measures for the PPIs, statins, renin-angiotensin inhibitor drugs (generic ACEIs vs. patented ARBs) and SSRIs. This mirrors the findings from other studies that multiple measures are needed to change physician prescribing habits

	However, there was limited change in the utilisation of losartan vs. other ARBs or risperidone versus other atypical antipsychotic drugs when generics became available in Scotland with no specific initiatives.. Consequently, health authorities cannot rely on a ‘spill over’ effect between classes to effect changes in physician prescribing habits, although exacerbated on this occasion by the complexity of the message for ARBs and the recognised need to tailor treatments for patients with psychotic illness

	High INN prescribing rates in Scotland (typically 98% or more across a number of molecules) suggest no problems generally with generics in routine care.

Five year review

There will continue to be scrutiny over pharmaceutical expenditure in Scotland particularly with ageing populations and the continued launch of new premium priced drugs. This includes the prescribing of existing patented drugs where generics are available in the class or related class as well as increasingly biosimilars as more biosimilars become available. Review articles such as this which consolidate the findings from multiple studies will help formulate and refine future health authority initiatives. 

Continued resource pressures will increase the focus on new premium priced drugs. This is likely to lead to new models to better plan and manage their entry as well as scrutinise subsequent prescribing against agreed guidance. In addition, increasingly monitor the safety and effectiveness of new drugs in practice, including the implications for any changes in service delivery, to further refine future guidance.
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